Sept 9 (Reuters) - NOVARTIS AG:
* TO ACQUIRE TOURMALINE BIO, COMPLEMENTING CARDIOVASCULAR
PIPELINE
WITH PACIBEKITUG FOR THE TREATMENT OF ATHEROSCLEROTIC
CARDIOVASCULAR DISEASE (ASCVD)
* OFFER PRICE USD 48 PER SHARE, COMPANY VALUED AT USD 1.4BN
* EXPECTS TO MERGE ACQUIRING SUBSIDIARY WITH AND INTO
TOURMALINE
* TRANSACTION IS EXPECTED TO CLOSE IN Q4 OF 2025
Source text:
Further company coverage:
(Gdansk Newsroom)